Balaji Prasad
Stock Analyst at Barclays
(3.31)
# 1,042
Out of 4,996 analysts
132
Total ratings
48.39%
Success rate
2.54%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $5.99 | +317.71% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $9.75 | +12.82% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $25.24 | -4.91% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $9.52 | -5.46% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $127.00 | +57.48% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $19.61 | -3.11% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $56.29 | +6.59% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $143.50 | +70.03% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $10.21 | +135.06% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $38.81 | -43.31% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $632.22 | -17.75% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $18.34 | +41.77% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.22 | +19.55% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.34 | +115.83% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.33 | +200.30% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.50 | +366.67% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $5.99
Upside: +317.71%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $9.75
Upside: +12.82%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $25.24
Upside: -4.91%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $9.52
Upside: -5.46%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $127.00
Upside: +57.48%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $19.61
Upside: -3.11%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $56.29
Upside: +6.59%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $143.50
Upside: +70.03%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $10.21
Upside: +135.06%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $38.81
Upside: -43.31%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $632.22
Upside: -17.75%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $18.34
Upside: +41.77%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.22
Upside: +19.55%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.34
Upside: +115.83%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.33
Upside: +200.30%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.50
Upside: +366.67%